Viganello

Researchers are conducting a Phase III international trial to study the effects and safety of androgen deprivation therapy ADT with or without darolutamide in men newly diagnosed with metastatic prostate cancer who have vulnerable functional abilities. This study specifically includes patients who have not chosen treatment with docetaxel or other androgen receptor pathway inhibitors. The goal is to evaluate how these treatments impact disease progression and patient health over time. Participants will be randomly assigned to one of two groups one receiving ADT plus darolutamide 600 mg taken orally twice daily, and the other receiving ADT plus a placebo taken with the same schedule. Treatment will continue until imaging shows disease progression or until the patient or doctor decides to stop for reasons such as side effects or other health issues. After stopping treatment, patients will enter a follow-up phase lasting up to 10 years to monitor survival, further treatments, and any ongoing or new side effects. During the study, participants will undergo regular assessments including imaging scans to check for cancer progression, blood tests, evaluations of urinary symptoms, and quality of life questionnaires. Researchers will track outcomes like progression-free survival, overall survival, symptom changes, and adverse events. Monitoring visits will occur periodically both during treatment and follow-up to gather comprehensive data on health status and treatment effects.

Researchers are reviewing anonymous medical records from multiple centers to understand the outcomes of different treatments for chronic pain. This study includes several groups to assess how various approaches work in distinct patient subgroups. The focus is on patients who have had or may have spinal cord stimulation systems or other treatments like radiofrequency RF or intradiscal therapies IDS. The study looks at patients who have previously received spinal cord stimulation or other therapies and those who have switched to different treatments afterward. Treatments under review include Boston Scientific devices and non-Boston Scientific systems such as spinal cord stimulation, RF, and IDS. The data is retrospective, meaning it examines past patient experiences without introducing new treatments. Participants involvement consists of the analysis of their de-identified medical charts, with no active treatment or visits required. Researchers will measure responder rates approximately two years from the start of data collection to evaluate treatment outcomes. The study spans from April 2012 to December 2030, focusing on long-term clinical results in chronic pain management.

Researchers are evaluating treatment options for older and frail patients aged 70 and above with metastatic non-small cell lung cancer NSCLC who have PD-L1 expression below 50%. This study focuses on comparing reduced-dose chemotherapy combined with cemiplimab against cemiplimab alone. The goal is to find a treatment that is both effective and better tolerated in this vulnerable group, who often face greater risks of side effects and poor tolerance to standard-dose chemotherapy. This randomized, open-label phase II trial assigns participants to one of two groups one receives reduced-dose platinum-doublet chemotherapy plus cemiplimab, and the other receives cemiplimab alone. The chemotherapy regimens vary slightly depending on cancer histology and are given every three weeks for four cycles, followed by maintenance cemiplimab treatment for up to two years or until disease progression or unacceptable side effects. Participants who experience disease progression may be eligible to switch to the combination therapy. Participants undergo regular assessments including CT scans and CNS imaging every 6 to 12 weeks, quality of life questionnaires, and geriatric-specific tests such as hand-grip strength at set intervals during treatment and follow-up. Researchers measure progression-free survival, overall survival, tumor response, treatment side effects, and patient-reported outcomes to evaluate treatment effectiveness and safety. The study aims to improve treatment decisions for older patients often excluded from clinical trials, ensuring their quality of life and functional status are considered.

Researchers are conducting a global, prospective, multi-center observational study to gather real-world data on the long-term effectiveness, economic value, and technical performance of Boston Scientifics commercially approved neurostimulation systems for pain management. The study focuses on patients using these neurostimulation devices according to their approved instructions for use in routine clinical practice. Participants will first undergo a neurostimulation trial period using any commercially approved Boston Scientific neurostimulator for pain. Those who experience a positive outcome from this trial may then receive a permanent implant of the neurostimulation system. Treatment customization will be guided by the investigators judgment and routine care practices at each site. During the study, participants will be observed to collect information on clinical outcomes, technical device performance, and economic factors related to neurostimulation therapy. The research team will monitor participants over the long term to assess how well the therapy manages pain and its associated benefits. The study is expected to continue until May 2035, with ongoing follow-up and data collection throughout this period.